Search details
1.
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study.
Lancet Oncol
; 25(2): e63-e72, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38301704
2.
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission.
Lancet Oncol
; 24(1): e11-e56, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36400101
3.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32997907
4.
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.
Eur J Nucl Med Mol Imaging
; 50(12): 3765-3776, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37474735
5.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37306090
6.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol
; 23(10): 1297-1307, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36063830
7.
Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling.
Rep Pract Oncol Radiother
; 27(6): 933-942, 2022.
Article
in English
| MEDLINE | ID: mdl-36632308
8.
Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer.
Neoplasma
; 68(2): 283-289, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33147053
9.
A View from the past into our collective future: the oncofertility consortium vision statement.
J Assist Reprod Genet
; 38(1): 3-15, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33405006
10.
Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report.
Int J Mol Sci
; 22(20)2021 Oct 10.
Article
in English
| MEDLINE | ID: mdl-34681595
11.
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
Oncologist
; 25(3): e598-e601, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32162818
12.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet
; 391(10126): 1163-1173, 2018 03 24.
Article
in English
| MEDLINE | ID: mdl-29433850
13.
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
Oncologist
; 24(1): e30-e37, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30181313
14.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(7): 975-986, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29880291
15.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 19(6): 799-811, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29753703
16.
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Breast Cancer Res Treat
; 172(2): 327-338, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30120700
17.
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
BMC Cancer
; 18(1): 295, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-29544445
18.
Systemic therapy for cervical carcinoma - current status.
Chin J Cancer Res
; 30(2): 209-221, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29861606
19.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28275117
20.
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 17(3): 357-366, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26822398